Prognostic Significance of Interim Response Evaluation during Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Simple Summary We investigated the clinical significance of interim response evaluation during definitive chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Interim response was evaluated using adaptive CT images including primary esophageal lesion and lymph node. The reduction rate of tumor area or diameter was measured. Interim response correlated with complete response and survival rates. That is, the evaluation of tumor burden reduction during treatment may help predict patient prognosis. Abstract The study aimed to investigate the clinical significance of interim response evaluation during definitive chemoradiotherapy (dCRT) in predicting overall treatment response and survival of patients with locally advanced esophageal squamous cell carcinoma (LAESCC). We reviewed 194 consecutive patients treated with dCRT for biopsy-confirmed LAESCC. A total of 51 patients met the inclusion criteria. Interim response was assessed by defining a region of interest in initial and adaptive computed tomography (CT) images and subsequently examined against the overall treatment response assessed three months after dCRT, treatment failure pattern, overall survival (OS), and progression-free survival (PFS) estimates. Reductions in both the area and maximal diameter of the primary lesion (p < 0.001; p < 0.001, respectively) and those of the metastatic lymph nodes (LN) (p = 0.002; p < 0.001, respectively) in interim analysis were significantly higher among patients who achieved complete response (CR) than among those who did not. OS was significantly longer among patients who showed ≥30% interim reduction in the area and maximal diameter of the primary lesion and among those who showed such reduction in both the primary lesion and LN. PFS was significantly longer in the patients with ≥30% interim reduction in the area of the primary lesion. In addition, the proportion of cases with locoregional failure began decreasing at interim response of 20% or higher, while the proportion of cases with outfield failure followed the opposite pattern, increasing at interim response of 20% or higher. Among patients treated with dCRT for LAESCC, interim response assessed using adaptive CT images correlated with overall CR and OS rates. The evaluation of tumor burden reduction during dCRT may help predict patient prognosis.

[1]  T. Mak,et al.  The role of Hippo‐YAP signaling in squamous cell carcinomas , 2020, Cancer science.

[2]  Lidong Wang,et al.  Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2 , 2020, Theranostics.

[3]  K. Kitajima,et al.  Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: multicenter study in Japan , 2020, Nuclear medicine communications.

[4]  Xue Wu,et al.  YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma , 2019, Cancer medicine.

[5]  Zhihua Wen,et al.  Yes-associated protein (YAP) predicts poor prognosis and regulates progression of esophageal squamous cell cancer through epithelial-mesenchymal transition , 2019, Experimental and therapeutic medicine.

[6]  Jan-Jakob Sonke,et al.  Adaptive Radiotherapy for Anatomical Changes. , 2019, Seminars in radiation oncology.

[7]  R. Yu,et al.  Outcomes and prognostic factors for patients with cervical esophageal cancer undergoing definitive radiotherapy or chemoradiotherapy. , 2019, Bosnian journal of basic medical sciences.

[8]  De-min Li,et al.  Correlation between Bax gene polymorphisms and esophagus cancer , 2018, Oncology letters.

[9]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[10]  Anhui Wang Epidemiology of Esophageal Squamous Cell Carcinoma , 2018 .

[11]  C. Hsieh,et al.  Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Wen-en Zhao,et al.  Potent hydrazone derivatives targeting esophageal cancer cells. , 2018, European journal of medicinal chemistry.

[13]  Jesper Lagergren,et al.  Oesophageal cancer , 2017, The Lancet.

[14]  M. Berry Esophageal cancer: staging system and guidelines for staging and treatment. , 2014, Journal of thoracic disease.

[15]  T. Borght,et al.  A Systematic Review of the Predictive Value of 18FDG-PET in Esophageal and Esophagogastric Junction Cancer After Neoadjuvant Chemoradiation on the Survival Outcome Stratification , 2014, Journal of Gastrointestinal Surgery.

[16]  J. Hwang,et al.  Clinical Prognostic Factors for Locally Advanced Esophageal Squamous Carcinoma Treated after Definitive Chemoradiotherapy , 2013, Cancer research and treatment : official journal of Korean Cancer Association.

[17]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[18]  J. Ajani,et al.  Nomograms for Prognostication of Outcome in Patients with Esophageal and Gastroesophageal Carcinoma Undergoing Definitive Chemoradiotherapy , 2012, Oncology.

[19]  Lin-jun Tong,et al.  Can 18F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis , 2011, Nuclear medicine communications.

[20]  R. M. Kwee Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. , 2010, Radiology.

[21]  J. Ajani,et al.  Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. , 2009, International journal of radiation oncology, biology, physics.

[22]  N. Khushalani Cancer of the esophagus and stomach. , 2008, Mayo Clinic proceedings.

[23]  P. Maingon,et al.  Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Kang,et al.  Low Expression of Bax Predicts Poor Prognosis in Patients with Locally Advanced Esophageal Cancer Treated with Definitive Chemoradiotherapy , 2007, Clinical Cancer Research.

[25]  F. Joubert,et al.  Bax/Bcl-2 expression levels of 2-methoxyestradiol-exposed esophageal cancer cells. , 2005, Biomedical research.

[26]  G. Noël,et al.  INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy , 2002 .

[27]  R. Ginsberg,et al.  INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  J. Cooper,et al.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. , 1999, JAMA.

[29]  J. Cooper,et al.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.

[30]  H. Kato,et al.  ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography for Evaluating the Response to Neoadjuvant Chemotherapy in Advanced Esophageal Cancer. , 2016, Anticancer research.

[31]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[32]  S. Law Chemoradiotherapy - panacea for esophageal cancer? Commentary for 'Chemoradiotherapy of locally advanced esophageal cancer. Long-term follow-up of a prospective randomized trial (RTOG 85-01)' , 1999 .